CompletedPhase 3NCT00636116

Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.

Studying Snakebite envenomation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Instituto Bioclon S.A. de C.V.
Principal Investigator
Walter García Ubbelohde, MD, MD
Instituto Bioclon
Intervention
Crotalinae (pit viper) equine immune F(ab)2(biological)
Enrollment
121 target
Eligibility
2-80 years · All sexes
Timeline
20082012

Study locations (18)

Collaborators

Universidad Nacional Autonoma de Mexico · University of Arizona

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00636116 on ClinicalTrials.gov

Other trials for Snakebite envenomation

Additional recruiting or active studies for the same condition.

See all trials for Snakebite envenomation

← Back to all trials